Core Viewpoint - Northeast Pharmaceutical is actively pursuing a strong start to Q1 2026 by focusing on production capacity, market expansion, and collaborative efforts across all departments to ensure high-quality operations throughout the year [1]. Group 1: Customer Audits and Production - Customer audits are crucial for product quality and management, serving as a key link to the market and stabilizing partnerships. As of January 14, Northeast Pharmaceutical successfully completed audits for 6 domestic and international clients, involving 4 production plants and 7 raw material products, all passing the reviews [2]. - The production front is identified as the core battlefield for achieving a strong start. Various production plants have mobilized to meet the surge in demand, with innovative strategies such as "modular rapid switching" and continuous operations during holidays to ensure timely delivery of customized orders [2]. Group 2: Data-Driven Sales and Cost Efficiency - The sales team is leveraging data to drive market opportunities, ensuring sufficient inventory for best-selling products and maintaining uninterrupted market supply. This proactive approach aims to expand growth potential for the strong start [3]. - Cost reduction and efficiency enhancement are vital for achieving a strong start. The production command center is implementing refined management practices, focusing on key data changes and organizing weekly meetings to analyze production cost indicators, thereby improving product competitiveness [3]. Group 3: Collaborative Innovation - Subsidiaries are actively contributing to the strong start through innovative approaches and a unified strategy. For instance, the technology service company has signed contracts with multiple clients to expand external markets, while logistics and design companies are enhancing efficiency and project delivery through innovative technologies [4]. - The overall strategy emphasizes collaboration across business lines, aiming for a coordinated effort to achieve the Q1 goals and support high-quality development throughout the year [4].

Core Viewpoint - Northeast Pharmaceutical is currently in a critical period of deep adjustment and transformation in the pharmaceutical industry, emphasizing the importance of each step in its development [1] Group 1: R&D and Strategic Transformation - Northeast Pharmaceutical is a significant drug production and export base in China, focusing on innovation-driven strategies and core business enhancement, achieving important results in R&D breakthroughs and quality improvement [2] - The company has increased R&D investment, aiming to accelerate the transition of innovative results from the laboratory to clinical applications [2] - The DCTY0801 injection, developed by its subsidiary, is set to undergo clinical trials for specific types of high-grade brain gliomas, marking a substantial breakthrough in cancer treatment innovation [2] - The acquisition of a 70% stake in DCTY0801's developer allows Northeast Pharmaceutical to quickly enter the cell therapy field, positioning it as a key platform for innovative drug development [3] - The company is committed to building a systematic and scalable talent cultivation system to enhance its R&D capabilities and facilitate its strategic shift from chemical pharmaceuticals to biological innovative drugs [3] Group 2: Quality Assurance and Market Expansion - Strong R&D capabilities provide essential support for product quality enhancement, which is crucial for global market competition [4] - The company’s core raw material product, Phosphomycin Amide, received the European Pharmacopoeia suitability certificate (CEP) in 2025, becoming the first domestic company to achieve this certification, enhancing its brand image and competitiveness in the international high-end market [4] - Northeast Pharmaceutical successfully passed a surprise inspection by the FDA, demonstrating its leading quality control system across the entire production and management chain [4] - The company is enhancing its quality management capabilities to support its expansion in both domestic and international markets [4] Group 3: Business Diversification and Value Enhancement - Northeast Pharmaceutical is expanding into related business areas, developing health food products based on the concept of "medicinal food homology" and launching a skincare brand, "Qifangyuan," to enter the beauty market [6] - The company’s diversification efforts are based on professional technology and aim to extend the value chain around the core of "health" [6] - The "Qifangyuan" brand integrates pharmaceutical technology and standards into skincare product development, showcasing the company's innovative approach [6] - Northeast Pharmaceutical is committed to optimizing its health product matrix and exploring comprehensive health services to create additional growth points [6] Group 4: Recognition and Achievements - The company’s improved business layout and solid operational results have enhanced its overall strength, leading to recognition from various sectors [7] - In 2025, Northeast Pharmaceutical was included in the list of recommended "National Intellectual Property Demonstration Enterprises" in Liaoning Province and re-certified as a national high-tech enterprise [7] - The company received the title of "Top 100 Pharmaceutical Industrial Enterprises by Revenue" for the 2024-2025 period in industry evaluations [7]

● 本报记者 宋维东 东北制药相关负责人日前在接受中国证券报记者采访时表示，当前正处在医药行业深度调整与转型的关 键时期，企业的每一步发展都至关重要。公司将认真总结发展经验，保持良好发展势头，以创新研发积 蓄未来势能，以卓越品质夯实市场根基，以人才战略激活内生动力，以多元布局拓宽成长边界，扎实推 动企业转型升级。 以研发助推战略转型 东北制药是我国重要的药品生产与出口基地之一，业务主要覆盖化学制药、医药商业、医药工程、生物 医药等板块。近年来，公司聚焦创新驱动与主业深耕，在研发突破与主业提质方面取得重要成果，构建 起了"研发创新破局、主业盈利稳盘、资产运营增效"的协同发展格局。 "研发创新是企业可持续发展的核心引擎。公司近年来持续加大研发投入，积极推动创新成果从实验室 加速走向临床。"东北制药上述负责人说。 2025年，东北制药控股子公司鼎成肽源自主研发的DCTY0801注射液获国家药品监督管理局批准，可开 展针对特定类型高级别脑胶质瘤的临床试验。这标志着东北制药在肿瘤治疗这一创新药研发关键赛道取 得了实质性突破，在丰富公司产品管线的同时，也为相关疾病领域治疗带来了新希望。 DCTY0801注射液是鼎成肽源管 ...

在替代项目评估阶段，东北制药创新性地建立了以"关键性、经济性、依赖性"为核心的多维评估模型， 严格执行技术对标与样品验证，确保了每一件替代备件的质量可靠。经过一年的不懈努力，东北制药国 产化替代工作取得显著成效。截至目前，团队已成功完成173项进口备件的国产化替代，累计创造经济 效益超200万元。一批曾经制约生产的"卡脖子"备件相继被攻克，不仅大幅降低了采购成本，更将关键 备件采购周期大幅缩短，为生产线的连续、稳定运行提供了坚实保障，有效增强了供应链的韧性与安 全。 在全力攻克进口替代难题的同时，东北制药同步深化内部挖潜，将国产化替代与全员创新紧密结合，广 泛开展修旧利废与技术革新活动。去年全年，公司累计完成修旧利废项目1081项、小改小革759项，不 仅有效优化了设备性能、提升了运行效率，更节约维修与配件费用超过220万元。这些内部挖潜举措与 进口备件国产化工作形成了有效协同，共同构筑起"重点攻关"与"全员改善"双轮驱动的创新生态，既解 决了生产实际问题，又培养了一批懂技术、善钻研的技能型人才，让自主创新的文化在基层一线蔚然成 风。 作为制造企业的"硬脊梁"，稳定高效的装备体系是保障产品质量、提升生产效率、 ...

证券日报网讯 1月8日，东北制药在互动平台回答投资者提问时表示，根据中国结算深圳分公司提供的 数据，截至2025年12月31日，公司股东人数约4.74万户。 （文章来源：证券日报） ...

根据《公司法》等法律法规及规范性文件的规定，公司于 2026 年 1 月 4 日召 开职工代表团（组）长联席会。经公司工会委员会提名及职工代表团（组）长联 席会民主表决，王新鹏先生（简历详见附件）当选为公司第十届董事会职工代表 董事，任期自公司职工代表团（组）长联席会选举产生之日起至第十届董事会任 期届满之日止。王新鹏先生符合《公司法》和《公司章程》等相关法律法规及规 范性文件对董事的任职资格和条件要求，其当选公司职工代表董事后，公司董事 会成员数量仍为 11 名，其中兼任公司高级管理人员以及由职工代表担任的董事人 数总计未超过公司董事总数的二分之一，符合相关法律法规及规范性文件的要求。 证券代码:000597 证券简称:东北制药 公告编号:2026-001 东北制药集团股份有限公司 关于非独立董事辞职暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（以下简称"公司"）董事会于近日收到非独立 董事王新鹏先生的书面辞职报告，因公司治理结构调整，王新鹏先生申请辞去公 司第十届董事会非独立董事职务，王新鹏先生辞去前述 ...

证券代码：000597 证券简称：东北制药 公告编号：2026-002 东北制药集团股份有限公司关于审计机构 变更项目质量控制复核人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召 开第十届董事会第七次会议审议通过了《关于拟变更会计师事务所的议案》，同 意聘任天职国际会计师事务所(特殊普通合伙)（以下简称"天职国际"）为公司 2025 年度财务报告及内部控制审计机构。该议案已获得公司于 2025 年 12 月 15 日召开的 2025 年第二次临时股东会审议通过。上述具体内容详见公司 2025 年 10 月 28 日披露于巨潮网的《东北制药集团股份有限公司关于拟变更会计师事务 所的公告》（公告编号：2025-067）。 近日，公司收到天职国际出具的《关于变更项目质量控制复核人的告知函》， 现将有关情况公告如下： 一、审计机构项目质量控制复核人变更情况 天职国际作为公司聘任的 2025 年度财务报告及内部控制审计机构，原委派 王军担任公司 2025 年度审计业务项目质量控制 ...

当天，针对档案出生时间与身份证信息不一致、调转材料缺失等退休办理常见堵点，人社局审批工作人 员现场进行政策解读并逐一解决，全程高效顺畅。 "现在人社部门上门服务，问题当场解决，业务一次办成。再也不用拎着大箱子满街跑了。"张娜的感 慨，说出了政企协同服务带来的实效，也印证了"下沉式"政务服务的政务温度。 "此次人社局'下沉'办公，不仅为企业员工带来了"零距离"便捷服务，更搭建起政企深度交流的坚实桥 梁。"沈阳市人社局企业养老保险处副处长齐卫军说。 "'现场办公+政策解读+互动问答'的服务模式带给我们的不仅仅便利，更能够提升公司人力资源团队的 业务水平，后续会持续释放出政企协同的叠加红利。"东北制药人力资源部负责人范迪说。 方大集团东北制药人力资源部经办员张娜的办公室里一直放着两只大拉杆箱，"过去给员工办理退休手 续，我要用这两个大拉杆箱装着厚厚的档案到人社部门，往返多个窗口，反复沟通补件。" 2025年年底，这两只大拉杆箱退休了。 2025年12月30日，沈阳市人力资源和社会保障局养老保险处的工作人员一行走进东北制药，开展退休审 批现场办公暨座谈活动，将政务服务"窗口"直接搬到企业一线，让员工退休办理实现从"多 ...

Core Insights - The core viewpoint of the articles emphasizes the significant advancements made by Northeast Pharmaceutical in its digital transformation, driven by "Artificial Intelligence+" to enhance production efficiency, optimize operational costs, and strengthen market competitiveness [1][2][3]. Group 1: Production Efficiency - The intelligent upgrade in production has become a key focus for the company to improve quality and efficiency. Northeast Pharmaceutical has built a localized knowledge base using DeepSeek, which allows for rapid fault diagnosis, reducing fault location time by over 80% [1]. - The implementation of AI-powered visual inspection equipment has replaced traditional manual checks, ensuring quality control by automatically identifying and removing non-compliant products, thus enhancing production scalability [2]. Group 2: Cost Optimization - The establishment of an energy monitoring system with over 3,000 data collection points has led to significant cost savings, achieving over 20 million yuan in energy efficiency gains within six months, aligning with green development goals and reducing unit production costs [2]. Group 3: Management Efficiency - The development of a big data analysis platform has broken down data silos across departments, enabling real-time data visualization and decision-making, which has transformed the decision-making process from experience-driven to data-driven [3]. - The company’s digital transformation is not merely a technological upgrade but a comprehensive reconfiguration of the entire pharmaceutical manufacturing value chain, aiming for enhanced operational efficiency, product quality, and cost control [3].

ni 生 第三代 : . 7 133 a 8 ddap al 商 t , ...